

DAFTAR PUSTAKA

- Adina, A. B., Goenadi, F. A., Handoko, F. F., Nawangsari, D. A., Hermawan, A., Jenie, R. I., and Meiyanto, E. 2012. Combination of ethanolic extract of *Citrus aurantifolia* peels with doxorubicin modulate cell cycle and increase apoptosis induction on MCF-7 cells. *Iranian. J. Pharm. Res.* 13(3):919-926.
- An, X., Tiwari, A. K., Sun, Y., Ding, P., Ashby, C. R., and Chen, Z. 2010. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review. *Leu. Res.* 34:1255-1268.
- Angst, E., Park, J. L., Moro, A., Lu, Q., Lu, X., Li, G., King, J., Chen, M., Reber, H. A., Go, V. L. W., Eibl, G., and Hines, O. J. 2013. The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo. *Pancreas.* 42(2):223-229.
- Bar-On, O., Shapira, M., and Hershko., D. 2007. Differential effect of doxorubicin treatment on cell cycle arrest and Skp2 expression in breast cancer cells. *Anti-cancer drugs.* 18:1113-1121.
- Betof, A. S., Rabbani, Z. N., Hardee, M. E., Kim, S. J. Brooadwater, G., Bentley, R. C., Snyder, S. A., Vujakovic, Z., Oosterwijk, E., Harris, L. N., Horton, J. K., Dewhirst, M. W., and Blackwell, K. L. 2012. Carbonic anhydrase IX is predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. *British. J. Cancer.* 106:916-922.
- Brouckaert, G., Kalai, M., Saelens, X., and Vandenabeele, P. 2005. Apoptotic pathways and their regulation. In: Los, M., Gibson, S.B. (Eds.), *Apoptotic Pathways as Target for Novel Therapies in Cancer and Other Diseases.* Springer Academic Press, New York.
- Campbell, N. A., Reece, J. B., Laurry, M. L., Cain, S. A., Wasserman, P. V., Minorsky, and Jackson, R. B. 2014. *Biology, 10th Edition.* San Fransisco:Pearson Education Benjamin Cummings. p : 235.
- Chandrika, B. B., Steephan, M., Kumar., T. R. S., Sabu, A., and Haridas, M. 2016. Hesperetin and naringenin sensitize HER2 positive cancer cells to detach by serving as HER2 Tyrosine Kinase inhibitor. *Life. Sci.* 16:47-56.
- Childs, C. A., Phaneuf., S. L., Dirks, A. J., Philips, T., and Leewenburgh., C. 2002. Doxorubicin treatment in vivo causes cythochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activitu, and Bcl-2:Bax ratio. *Cancer. Res.* 62:4592-4598.

- Chou, T. 2006. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. *Pharmacol. Rev.* 58:621-681.
- Cortes-Funes, H. and Coronado, C. 2007. Role of anthracyclines in the era of targeted therapy. *Cardiovasc. Toxicol.* 7:56-60.
- Davis, J. M., Navolanic, P. M., Weinten-Openheimer, C. R., Steelman, L. S., Hu, W., Konopleva, M., Blagosklonny, M. V., and McCubrey, J. A. 2003. Raf-1 and Bcl-2 induce distinct and common pathway that contribute to breast cancer drug resistance. *Clin. Cancer. Res.* 9:1161-1170.
- English, D. P., Roque, D. M., and Santin, A. D. 2013. HER2 expression beyond breast cancer: therapeutic implication for gynecologic malignancies. *Mol. Diagn. Ther.* 17(2):85-99.
- Febriansah, R., Putri, D. P. P., Sarmoko, Nurulita, N. A., Meiyanto, E., and Nugroho, A. E. 2014. Hesperidin as a preventive resistance agent in MCF-7 breast cancer cells line resistance to doxorubicin. *Asian. Pac. J. Trop. Biomed.* 4(3):228-233.
- Fernandez, P. L., Jares, P., Rey, M. J., Campo, E., and Cardesa, A. 1998. Cell cycle regulators and their abnormalities in breast cancer. *Clin. Pathol. Mol. Pathol. J.* 51:305-309.
- Fisk, B., Blevins, T. L., Wharton, J. T., and Ioannides, C. G. 1995. Identification of and immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. *J. Exp. Med.* 181:2109-2117.
- Foster, I. 2008. Cancer: a cell cycle defect. *Rad.* 14:144-149.
- Fujii, T., Kawahara, A., Basaki, Y., Hattori, S., Nakashima, K., Nakano, K., Shirouzu, K., Kohno, K., Yanagawa, T., Yamana, H., Nishio, K., Ono, M., Kuwano, M., and Kage, M., 2008. Expression of HER2 and estrogen receptor α depend upon nuclear localization of Y-Box Binding Protein-1 in human breast cancer. *Cancer. Res.* 68(5):1504-1512.
- Fulda, S., Meyer, E., and Debatin, K. 2002. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. *Oncogene.* 21:2283-2294.
- Garg, A., Garg, S., Zaneveld, L. J. D., and Singla, A. K. 2001. Chemistry and pharmacology of the citrus bioflavonoid hesperidin. *Phytoter. Res.* 15:655-669.
- Gewirtz, D. A. 1999. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. *Biochem. Pharm.* 57:727-741.
- Ghorbani, A., Nazari, M., Jeddi-Tehrani, M., and Zand, H. 2012. The citrus flavonoid hesperidin induces p53 and inhibits NF- κ B activation in order to

- trigger apoptosis in NALM-6 cells: involvement of PPAR γ -dependent mechanism. *Eur. J. Nutr.* 51:39-46.
- Gnapreddy, B., Dugasani, S. R., Ha, T., Paulson, B., Hwang, T., Kim, T., Kim, J. H., Oh, K., and Park, S. H. 2015. Chemical and physical characteristics of doxorubicin hydrochloride drug-doped salmon DNA thin films. *Scientific Report.* 5:12722.
- Hermawan, A., Meiyanto, E., dan Susidarti, R. A. 2010. Hesperidin meningkatkan efek sitotoksik doxorubicin pada sel MCF-7. *Majalah Farmasi Indonesia.* 21(1):8-17.
- Holliday, D., and Speirs, V. 2011. Choosing the right cell line for breast cancer research. *Breast. Cancer. Res.* 13:215-222.
- Kalra, J., Sutherland, B. W., Starford, A. L., Dragowska, W., Gelmon, K. A., Dedhar, S., Dunn, S. E., and Bally, M. B. 2010. Suppression of HER2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1. *Oncogene.* 29:6343-6356.
- Khedr, N. R. and Khalil, R. M. 2015. Effect of hesperidin on mice bearing Ehrlich solid carcinoma maintained on doxorubicin. *Tumour. Biol.* 36(12):9267-9275.
- Kolch, W., Kotwaliwale, A., Vass, K., and Janosch, P. 2002. Mitogens driver cell cycle progression by induction cyclin D inactivation of the retinoblastoma (Rb) protein. *Expert Reviews in Molecular Medicine.* Cambridge Univ Press.
- Kusharyanti, I., Larasati, Susidarti, R. A., and Meoyanto, E. 2011. Hesperidin Increase Cytotoxic Activity of Doxorubicin on Hela Cell Line Through Cell Cycle Modulation and Apoptosis Induction Indonesian. *J. Cancer. Chemo.* 2(2):267-273.
- Landers, J. E., Cassel, S. L., and George, D. L. 1997. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. *Cancer. Res.* 57:3562-3568.
- Lasham, A., Print, C. G., Wooley, A. G. Dunn, S., and Braithwaite, A. W. 2013. YB-1 : oncoprotein, prognostic marker, and therapeutic target? *Biochem. J.* 449:11-23.
- Lee, A. V., Oesterreich, S., and Davidson, N. E. 2015. MCF-7 cells-changing the course of breast cancer research and care for 45 years. *J. Natl. Cancer. Inst.* 107(7):djvo73.
- Lee, C. J., Wilson, L., Jordan, M. A., Nguyen, V., Tang, J., and Smiyun, G. 2010. Hesperidin suppressed proliferations of both human breast cancer and androgen-dependent prostate cancer cells. *Phytoter. Res.* 24:15-19.

- Lee, K., Lee, S., Lee, Y., Baeg, S. M., and Shim, J. 2012. Hesperidin induces apoptosis by inhibiting Sp1 and its regulatory protein in MSTO-211H cells. *Biomol. Ther.* 20(3):273-279.
- Meiyanto, E., Hermawan, A., and Anindyajati. 2012. Natural product for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents. *Asian. Pacific. J. Cancer. Prev.* 13:427-436.
- Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., and Gianni, L. 2004. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. *Pharm. Rev.* 56:185-229.
- Mitri, Z., Constantine, T., and O'Regan, R. 2012. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. *Chemother. Res. Pract.* 2012.
- Moasser. 2007. The oncogene HER2; its signalling and transforming functions and its role in human cancer pathogenesis. *Oncogene.* 26(45):6469-6487.
- Morand, C., Dubray, C., Milenkovic, D., Lioger, D., Martin, J. F., Scalbert, A., and Mazur, A. 2012. Hesperidin contributes to the vascular protective effects of orange juice: randomized crossover study in healthy volunteers. *Am. J. Clin. Nutr.* 93:73-80.
- Mughal, A., Aslam, H. M., Khan, A. M. H., Saleem, S., Umah, R., and Saleem M. 2013. Bcr-Abl tyrosine kinase inhibitors-current status. 2013. *Infect. Agn. Cancer.* 8:23-25.
- Nahta, R. 2012. Molecular mechanisms of trastuzumab-based treatment in HER2-overexpressing breast cancer. *ISRN. Oncology.* 8(6):215-222.
- Padanilam, B. J. 2003. Cell death induced by acute renal injury: a perspective on the contributions a apoptosis and nekrosis. *Am. J. Physiol. Renal. Physiol.* 284:608-627.
- Paul, M. K. and Mukhopadhyay, A. K. 2004. Tyrosine kinase-role and significance in cancer. *Int. J. Med. Sci.* 1(2):101-115.
- Raimondo, S., Naselli, F., Fontana, S., Monteleona, F., Lo Dico, A., Saieva, L., Zito, G., Flugy, A., Manno, M., Di Bella, M. A., De Leo, G., and Alessandro, R. 2015. Citrus limon-derived nanovesicles inhibit cancer cell proliferation and suppress CML xenograft growth by inducing TRAIL-mediated cell death. *Oncotarget.* 6(23):19514-19527.
- Rao, V., K. and Oliveira, J. B. 2011. How I treat autoimmune lymphoproliferative syndrome. *Blood.* 118(22):5741-5751.
- Rastogi, P. R., Richa, and Sinha, R. P. 2009. Apoptosis: molecular mechanisms and pathogenicity. *EXCLI. J.* 8:155-181.
- Riese, D. J. and Stern D. F. 1998. Specificity within the EGF family/ErbB receptor family signalling network. *Bio. Essays.* 20:41-48.

- Rizza, S., Muniyappa, R., Latorno, M., Kim, J., Chen, H., Pullikotil, P., Senese, N., Tesauro, M., Lauro, D., Cardillo, C., and Quori, M. J. 2011. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. *J. Clin. Endocrinol. Metab.* 96(5):E782-E792.
- Roohbakhsh, A., Parhiz, H., Soltani, F., Razaee, R., and Iranshahi. 2015. Molecular mechanisms behind the biological effects of hesperidin and hesperetin for the prevention of cancer and cardiovascular diseases. *Life. Sci.* 1(124):64-74.
- Sakarkar, D. M. and Deshmukh, V. N. 2011. Ethnopharmacological review of traditional medicinal plants for anticancer activity. 3(1):298-308.
- Schulz, W.A., 2005. *Molecular Biology of Human Cancer*. Springer, USA.
- Sharma, G. N., Dave, R., Sanadya, J., Sharma, P., and Sharma, K. K. 2010. Various types and management of breast cancer: an overview. *J. Adv. Pharm. Technol. Res.* 1(2):109-126.
- Sibernagl, S. and Lang, F. 2000. *Color Atlas of Pathophysiology*. Thieme. Stuttgart, New York.
- Siddiqa, A., Long, M. L., Li, L., Marciniak, R. A., and Kazhdan, I. 2008. Expression of HER-2 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathway. *BMC. Cancer.* 8:129-137.
- Silke, J. and Meier, P. 2013. Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. *CSH. Perspect. Biol.* 5(2):a008730.
- Singh, L., Pushker, N., Saini, N., Sen, S., Sharma, A., Bakhshi, S., Chawla, B., and Kashyap, S. 2014. Expression of pro-apoptotic Bax and anti-apoptotic Bcl-2 proteins in human retinoblastoma. *Clin. Exp. Ophthalmol.* 43(3):259-267.
- Smith, L., Watson, M. B., O’Kane, S. L., Drew, P. J., Lind, M. J., and Cawkwell, L. 2006. The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. *Mol. Cancer. Ther.* 5(8):2115-2120.
- Soule, H. D. Vazquez, J., Long, A., Albert, S., and Brennan, M. 1973. A human cell line from a pleural effusion derived from breast cancer carcinoma. *J. Nat. Cancer. Inst.* 51(5):1409-1416.
- Supriya, R., Tam, B. T., Pei, X. M., Lai, C. W. Chan, L. W., Yung B. Y. and Siu, P. M. 2016. Doxorubicin induces inflammatory modulation and metabolic dysregulation in diabetic skeletal muscle. *Physiol.* 7:1-13.

- Tacar, O., Sroamornsak, P., and Dass, C. R. 2012. Doxorubicin; an update on anticancer molecular action, toxicity and novel drug delivery systems. *J. Pharm. Pharmacol.* 65(2):157-170.
- Tal, M., Wetzler, M., Josefberg, Z., Deutch, A., Gutman, M., Assaf, D., Kris, R., Shiloh, Y., Givol, D., and Schlessinger, J. 1988. Sporadic amplification of HER2/neu protooncogene in adenocarcinomas of various tissues. *Cancer Res.* 48:1517-1520.
- Taylor, W. R. and Stark, G. R. 2001. Regulation of the G2/M transition by p53. *Oncogene.* 20:1803-1815.
- Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., and Altman, R. B. 2011. Doxorubicin pathways: pharmacodynamics and adverse effects. *21(7):440-446.*
- Tokarska-Schlattner, M., Zaugg, M., Zuppinger, C., Wallimann, T., and Schlattner, W. 2006. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. *J. Mol. Cell. Card.* 41:389-405.
- Wang, S., Konorev, E. A., Srigiridhar, K., Joseph, J., Kalivendi, S., and Kalyanaraman, B. 2004. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. *279(24):25535-25543.*
- Wang, Y., Yu, H., Zhang, J., Gao, J., Ge, X., and Lou, G. 2015. Hesperidin inhibits HeLa cell proliferation through apoptosis mediated by endoplasmic reticulum stress pathway and cell cycle arrest. *BMC. Cancer.* 15:682-692.
- Wojcik, T., Buzcek, E., Majzner, K., Kolodziejczyk, A., Miszyk, J., Kaczara, P., Kwiatek, W., Baranska, M., Szymonski, M., and Chlopicki, S. 2015. Comparative endothelial profiling doxorubicin and daunorubicin in cultures endothelial cells. *Toxicology in vitro.* 29:512-521.
- Wolf-Yadlin, A., Kumar, N., Zhang, Y., Hauteniemi, S., Zaman, M., Kim, H., Grantcharova, V., Lauffenburger, D. A., and White, F. M. 2006. Effects of HER2 overexpression on cell signalling networks governing proliferation and migration. *Mol. Sys. Biol.* 2:54-68.
- Wong, R. S. Y. 2011. Apoptosis in cancer: from pathogenesis to treatment. *J. Exp. Clin. Cancer Res.* 30:87-100.
- WHO. 2014. World cancer report. 2014. Edited by Bernard W. S. and Christopher P.W. International Agency for Research on Cancer.
- Zhao, S., Ohara, S., Kanno, Y., Midorikawa, Y., Nakayam, M., Makimura, M., Park, Y., and Inouye, Y. 2013. HER2 overexpression-mediated inflammatory signalling enhances mammosphere formation through up-regulation of aryl hydrocarbon receptor transcription. *Cancer.Letters.* 330(2013):41-48.

Zielinska-Przyjemska, M. and Ignatowicz, E. 2008. Citrus fruit flavonoids influence on neutrophil apoptosis and oxidative metabolism. *Phytother. Res.* 22:1557-1562.